In another cohort study conducted at The University of Texas MD Anderson Cancer Center, fecal samples were collected from 112 metastatic melanoma patients before and after the anti-PD-1 antibody treatment, and the correlations between the diversity and compositions of the intestinal flora and the clinical responses were analyzed [63]. The gene discussed is PDCD1; the disease is metastatic melanoma.